RCM Applied sciences (NASDAQ:RCMT) rose as a lot as 21.2% on Monday after B. Riley upgraded the inventory to Purchase from Impartial after its Q2 earnings report.
The brokerage reiterated its $23 worth goal on RCMT, which means potential upside of 69% to final shut. The PT represents a conservative 8x a number of on 2022E EV/EBITDA.
“Market share beneficial properties, sturdy end-market tailwinds, and company-specific actions led to important progress in 2022 with bettering prospects for 2023,” analyst Alex Rygiel wrote in a notice to purchasers.
B. Riley raised RCMT’s adj. EBITDA estimate for 2022 to $30.0M (from $29.6M) and for 2023 to $34M (from $32.3M).
RCMT inventory slid after the corporate reported largely in-line Q2 outcomes, ending 21.31% decrease. B. Riley attributed the drop in inventory worth to short-term retail buying and selling exercise.
The brokerage mentioned weaker inventory worth provided institutional buyers a sexy entry level because the shares at the moment commerce at 4.6x 2022 EV/EBITDA, a reduction to B. Riley’s sum-of-the-parts peer-weighted common of seven.3x.
In response to SA Quant, RCMT is a Robust Purchase because the inventory scored extremely in issue grades progress, profitability, momentum and estimate revisions.
Shares of RCMT greater than doubled in worth YTD and elevated practically fourfold within the final 1 yr.
